Sunho Biologics (HKSE:02898) Total Operating Expense: HK$96.97 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02898 Sunho Biologics Inc HKSE:02898
11 GF Score
Price HK$6.39
! 1 Warning Sign
View Full Analysis

What is Sunho Biologics Total Operating Expense?

Sunho Biologics HKSE:02898 11 Total Operating Expense is HK$96.97 Mil as of Jun. 2025. GuruFocus rates HKSE:02898 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Sunho Biologics's Total Operating Expense for the six months ended in Jun. 2025 was HK$45.28 Mil. Sunho Biologics's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 was HK$96.97 Mil.

Sunho Biologics Total Operating Expense Related Terms

Sunho Biologics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Sunho Biologics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunho Biologics Total Operating Expense Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
Total Operating Expense
52.13 72.64 108.21

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Operating Expense Get a 7-Day Free Trial 56.59 16.13 56.99 51.69 45.28
HKSE:02898
11GF Score
Sunho Biologics Inc HKSE:02898
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunho Biologics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$96.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of HK$96.97 Mil mean?
Sunho Biologics (HKSE:02898) has a Total Operating Expense of HK$96.97 Mil as of Jun. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sunho Biologics and its competitors.
Is Sunho Biologics' Total Operating Expense too high?
Sunho Biologics' current Total Operating Expense is HK$96.97 Mil. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' Total Operating Expense compare to VRTX and REGN?
Sunho Biologics' Total Operating Expense of HK$96.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sunho Biologics and its competitors. Sunho Biologics's current Total Operating Expense is HK$96.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current Total Operating Expense of HK$96.97 Mil. The current Total Operating Expense is HK$96.97 Mil. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current Total Operating Expense is HK$96.97 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunho Biologics Business Description

Address No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score

Get the complete analysis for HKSE:02898

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.39
Price